Sankyo selects Evotec as assay development, screening partner

By E. Janene Geiss

Philadelphia, April 27 - Evotec AG said Thursday that Sankyo, a wholly owned subsidiary of Daiichi Sankyo Co. Ltd., has chosen Evotec as a partner to identify small molecule therapeutics for their pharmaceutical discovery projects.

Evotec said it will apply its skills and proprietary technologies in assay development and ultra-high throughput screening to identify biologically active molecules from its corporate library that interact with disease targets selected by Sankyo, according to a company news release.

Compounds identified in screening will be further characterized and prioritized by Evotec for progression into Sankyo's subsequent lead optimization programs, officials said.

No financial details were released.

Evotec is a Hamburg, Germany, pharmaceutical company developing small molecule-based drugs.

Daiichi Sankyo is a Tokyo-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.